cancer
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…
First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –
The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…
The findings of a recent study suggest that tilimycin-producing bacteria can cause genetic mutations in the colon and increase a person’s susceptibility to disease.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
The bacterial strains in MB097 were identified by analysing the microbiome of patients in multiple studies of ICIs in melanoma.
The findings of a new study suggest that the microbial metabolite 3-IAA could help to treat PDAC.
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the…
Collaboration joins MD Anderson's expertise and capabilities with Fed Bio's proprietary ACT bacterial cell therapy platform to design and manufacture a complex, synthetic microbiome-based therapy
